An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer

OBJECTIVE: BRCA-positive ovarian cancer patients derive benefit PARP inhibitors. Approximately 50% of ovarian cancer tumors have homologous recombination (HR) deficiencies and are therefore “BRCA-like,” possibly rendering them sensitive to PARP inhibition. However, no predictive assay exists to iden...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Shah, Monjri M., Dobbin, Zachary C., Nowsheen, Somaira, Wielgos, Monica, Katre, Ashwini A., Alvarez, Ronald D., Konstantinopoulos, Panagiotis A., Yang, Eddy S., Landen, Charles N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4221419/
https://ncbi.nlm.nih.gov/pubmed/24844596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2014.05.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados